ClinicalTrials.gg

Program

MK-1167

A development code.

Its studies are mostly in Alzheimer Disease, led by Merck.

Furthest: phase 2, since Dec 3, 20246 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck60 open or runningphase 2since Dec 3, 2024Feb 22, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 22, 2024First study: phase 1 study in Alzheimer DiseaseFirst studyNCT06285240 · 28 enrolled · United States
  2. Oct 1, 2024Phase 1 study in HealthyNCT06625840 · 16 enrolled · United States
  3. Nov 21, 2024Phase 1 study in HealthyNCT06703463 · 16 enrolled · United States
  4. Dec 3, 2024Phase 2 study in Alzheimer DiseaseNCT06721156 · 369 enrolled · United States, Argentina, Canada and more
  5. Dec 1, 20252 phase 1 studies in HealthyNCT07266818, NCT07334860

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07334860Healthy · United States1CompletedMay 20, 202616
NCT07266818Healthy · United States1CompletedApr 9, 202630
NCT06721156Alzheimer Disease · United States, Argentina, Canada and more2TerminatedJun 5, 2026369
NCT06703463Healthy · United States1CompletedFeb 2, 202416
NCT06625840Healthy · United States1CompletedMay 8, 202416
NCT06285240Alzheimer Disease · United States1CompletedSep 23, 202428

How it is read

Names in the registry

  • “MK-1167”, 6 entries

Codes read as this program: MK1167.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
MK-1167 (Merck): development program | ClinicalTrials.gg